Memo Therapeutics AG has entered into a collaboration and option agreement with CSL to advance the development of its recombinant polyclonal IgG technology. The partnership includes funding from CSL to support research and development activities focused on exploratory work related to this technology.
Under the agreement, both companies will work together to enhance the potential applications of Memo Therapeutics’ recombinant polyclonal antibodies, aiming to create innovative therapeutic solutions.
**Why this matters**
This collaboration combines Memo Therapeutics’ expertise in recombinant polyclonal antibody technology with CSL’s resources and experience in biopharmaceutical development. The partnership could accelerate the advancement of new antibody-based treatments, potentially benefiting patients with complex diseases that require multi-targeted therapeutic approaches.
Source: NewsData